Obesity Management Market
Obesity Management Market is segmented by Drug Type (Liraglutide, Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate), Surgery Type (Gastric Bypass Surgery, Adjustable Gastric Banding Surgery, Gastric Sleeve Surgery, Duodenal Switch Surgery, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-commerce), and Region. Forecast for 2026 to 2036.
Obesity Management Market Size, Market Forecast and Outlook By FMI
Summary of the Obesity Management Market
- Demand and Growth Drivers
- Rising global obesity prevalence is expanding the patient population eligible for pharmacological and surgical weight management interventions across developed and emerging markets.
- GLP-1 receptor agonist drug approvals including semaglutide and tirzepatide are transforming the obesity treatment landscape by demonstrating clinically meaningful weight loss in large scale trials.
- Bariatric surgery demand is sustained by established long term outcomes data demonstrating durable weight loss, metabolic improvement, and reduced comorbidity burden in patients with severe obesity.
- Product and Segment View
- Gastric Bypass Surgery holds 45.0% of the surgery type segment in 2026, reflecting established clinical evidence for sustained weight loss and metabolic improvement outcomes.
- Liraglutide accounts for 34.0% of the drug type segment, supported by established prescriber familiarity, insurance coverage, and a broad approved indication base.
- Hospital Pharmacies hold 30.0% of the distribution channel, reflecting the concentration of obesity drug dispensing in hospital based weight management programs.
- Geography and Competitive Outlook
- The USA is expected to register a CAGR of 5.2% through 2036, driven by high obesity prevalence, GLP-1 agonist adoption, and bariatric surgery infrastructure.
- South Korea at 5.1% reflects growing obesity rates, expanding pharmaceutical treatment options, and increasing bariatric surgery adoption.
- Novo Nordisk leads through its Wegovy (semaglutide) franchise and established position in obesity pharmacotherapy.
- Analyst Opinion
- 'Obesity management is transitioning from a surgical niche to a broad therapeutic category. The commercial success of GLP-1 receptor agonists is reshaping treatment pathways and creating pharmaceutical market opportunities that dwarf historical surgical volumes,' says Sabyasachi Ghosh, Managing Director at FMI.
- The market is being restructured by GLP-1 agonist efficacy data that is shifting first-line obesity treatment from lifestyle intervention alone toward combined pharmacological and behavioral approaches.
- Adoption of pharmacological obesity treatment is increasing as clinical evidence demonstrates weight loss outcomes approaching surgical results for some patient populations.
- Demand is further shaped by employer and payer interest in obesity treatment coverage as evidence links weight management to reduced downstream healthcare costs.
Obesity Management Market Definition
The Obesity Management Market covers pharmaceutical drugs and surgical procedures used for weight management in patients with obesity and overweight conditions with comorbidities. Products include pharmacological treatments (liraglutide, bupropion and naltrexone, orlistat, lorcaserin, phentermine and topiramate) and surgical interventions (gastric bypass, adjustable gastric banding, gastric sleeve, duodenal switch).
Obesity Management Market Inclusions
Market scope includes all commercially traded obesity management products classified by drug type, surgery type, distribution channel (hospital pharmacies, retail pharmacies, e-commerce), and route of administration (oral, injectable). Revenue coverage spans 2026 to 2036.
Obesity Management Market Exclusions
The scope does not include dietary supplements for weight management, fitness equipment, meal replacement products, or cosmetic body contouring procedures.
Obesity Management Market Research Methodology
- Primary Research: FMI analysts conducted interviews with industry participants, technology providers, and end users across key markets.
- Desk Research: Combined data from industry associations, regulatory filings, and manufacturer disclosures.
- Market Sizing and Forecasting: Bottom up aggregation across segments and regions with top down validation.
- Data Validation: Cross checked quarterly against industry data and manufacturer disclosures.
Why is the Obesity Management Market Growing?
- GLP-1 receptor agonist adoption is accelerating as clinical trial data demonstrates 15 to 20% average body weight reduction, shifting treatment paradigms from surgery first to pharmacotherapy first for many obese patient populations.
- Bariatric surgery remains the established intervention for severe obesity, with long term data demonstrating sustained weight loss exceeding 25% and significant improvement in type 2 diabetes, hypertension, and cardiovascular risk factors.
Demand for obesity management reflects the convergence of rising global obesity prevalence and the emergence of pharmacological treatments that demonstrate clinically meaningful weight loss for the first time. GLP-1 receptor agonists, particularly semaglutide (Wegovy) and tirzepatide (Zepbound), have demonstrated average weight losses of 15 to 22% in clinical trials, fundamentally changing the treatment landscape. These results approach surgical outcomes for moderate obesity and have shifted clinical guidelines toward earlier pharmacological intervention.
The bariatric surgery market continues to grow as a treatment option for severe obesity where pharmacological approaches are insufficient or contraindicated. Gastric bypass and gastric sleeve procedures have accumulated extensive long term outcomes data demonstrating durable weight loss, diabetes remission, and cardiovascular risk reduction. Surgery remains the most effective intervention for patients with BMI above 40 or BMI above 35 with significant comorbidities.
Payer coverage is expanding as health economic evidence demonstrates that obesity treatment reduces long term healthcare costs associated with diabetes, cardiovascular disease, and other obesity related conditions. Insurance coverage for GLP-1 agonists and bariatric surgery is broadening, which removes a significant access barrier and expands the addressable treated patient population.
Market Segmentation Analysis
- Gastric Bypass Surgery holds 45.0% of the surgery type segment, reflecting established long term outcomes data for durable weight loss and metabolic improvement.
- Liraglutide accounts for 34.0% of the drug type segment, supported by established prescriber familiarity and broad insurance coverage.
The Obesity Management Market is segmented by drug type, surgery type, distribution channel, and route of administration. Gastric Bypass Surgery leads the surgical segment. Liraglutide leads the drug type segment as an established pharmacological option.
Insights into the Gastric Bypass Surgery Segment
In 2026, Gastric Bypass Surgery is expected to represent 45.0% of the surgery type segment. Roux-en-Y gastric bypass combines restrictive and malabsorptive mechanisms to achieve sustained weight loss exceeding 25% of initial body weight in most patients.
Growth reflects the established evidence base demonstrating superior long term outcomes compared to other bariatric procedures for patients with severe obesity and metabolic comorbidities.
Insights into the Liraglutide Drug Type Segment
Liraglutide accounts for 34.0% of the drug type segment in 2026. Saxenda (liraglutide 3.0mg) was among the first GLP-1 agonists approved specifically for chronic weight management.
While newer agents including semaglutide demonstrate greater efficacy, liraglutide retains significant market share due to established prescriber familiarity, broad insurance coverage, and patient experience across a large treated population.
Obesity Management Market Drivers, Restraints, and Opportunities
- Rising obesity prevalence and GLP-1 agonist adoption are transforming the obesity treatment landscape from a surgical niche to a broad pharmaceutical market.
- Drug cost and access barriers including high GLP-1 agonist pricing and limited insurance coverage constrain patient access in many markets.
- Long term efficacy and safety data accumulation for newer pharmacological agents will determine the pace of market expansion and treatment paradigm shifts.
The Obesity Management Market is shaped by pharmaceutical innovation, surgical evidence, and payer coverage dynamics. Growth is supported by GLP-1 agonist efficacy, while barriers include drug costs and access limitations.
GLP-1 Receptor Agonist Adoption
Demand is shaped by the demonstrated efficacy of GLP-1 receptor agonists in producing clinically meaningful weight loss. Semaglutide and tirzepatide trial results are expanding prescriber and patient interest in pharmacological obesity treatment.
Drug Cost and Access Barriers
Growth is moderated by the high monthly cost of GLP-1 agonists and inconsistent insurance coverage across markets. Out of pocket costs exceeding USD 1,000 per month in the USA limit patient access and sustained adherence.
Bariatric Surgery Evidence Base
Adoption of surgical interventions is supported by long term outcomes data demonstrating durable weight loss and comorbidity improvement that sustain bariatric surgery as the preferred intervention for severe obesity.
Analysis of Obesity Management Market By Key Countries
.webp "Top Country Growth Comparison Obesity Management Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| USA | 5.2% |
| South Korea | 5.1% |
| Japan | 5% |
| European Union | 4.9% |
| UK | 4.7% |
- The USA leads with a 5.2% CAGR through 2036, driven by high obesity prevalence, GLP-1 agonist adoption, and established bariatric surgery infrastructure.
- South Korea at 5.1% reflects growing obesity rates and expanding treatment availability.
- Japan (5.0%) and the EU (4.9%) show steady growth driven by pharmaceutical approvals and surgical adoption.
The global Obesity Management Market is projected to grow at a CAGR of 4.9% from 2026 to 2036. The analysis covers more than 30 countries.
Demand Outlook for Obesity Management Market in the United States
The USA is expected to grow at 5.2% through 2036, anchored in high obesity prevalence, GLP-1 agonist adoption, and bariatric surgery capacity.
- High obesity prevalence creates a large addressable patient population.
- GLP-1 agonist prescribing is expanding across primary care and endocrinology.
- Bariatric surgery infrastructure supports growing surgical procedure volumes.
Future Outlook for Obesity Management Market in South Korea
South Korea is expected to grow at 5.1% through 2036, reflecting rising obesity rates and expanding treatment access.
- Rising obesity rates expand the patient population seeking treatment.
- Pharmaceutical treatment options are broadening with new drug approvals.
- Bariatric surgery adoption is growing in major hospital networks.
Opportunity Analysis of Obesity Management Market in Japan
Japan is expected to grow at 5.0% through 2036, driven by metabolic syndrome awareness, pharmaceutical treatment adoption, and surgical infrastructure.
- Metabolic syndrome screening programs identify patients for early intervention.
- GLP-1 agonist approvals expand pharmacological treatment options.
- Surgical capabilities support bariatric procedure adoption for severe obesity.
In-depth Analysis of Obesity Management Market in the European Union
The European Union is expected to grow at 4.9% through 2036, reflecting pharmaceutical treatment expansion and EU health system obesity management programs.
- EU health system obesity programs support treatment access expansion.
- Pharmaceutical treatment guidelines incorporate GLP-1 agonists for eligible patients.
- Bariatric surgery centers provide surgical options for severe obesity.
Sales Analysis of Obesity Management Market in the United Kingdom
The UK is expected to grow at 4.7% through 2036, supported by NHS obesity management programs and NICE approved treatments.
- NHS obesity management programs support structured treatment pathways.
- NICE approved medications expand pharmaceutical treatment access.
- Bariatric surgery availability supports surgical intervention for severe obesity.
Competitive Landscape and Strategic Positioning
- Novo Nordisk leads through its Wegovy (semaglutide) franchise and established dominance in GLP-1 receptor agonist based obesity pharmacotherapy.
- Eli Lilly and Company, Johnson and Johnson (Ethicon), and Medtronic maintain positions through pharmaceutical pipelines and bariatric surgical device portfolios.
- Emerging players target niche opportunities including intragastric balloons, endoscopic bariatric procedures, and combination pharmacological approaches.
Novo Nordisk maintains a leading position through Wegovy (semaglutide 2.4mg) which has established a dominant franchise in obesity pharmacotherapy. Eli Lilly and Company is positioned with tirzepatide (Zepbound) as a competitive alternative.
Johnson and Johnson (Ethicon) provides bariatric surgical instruments and staplers. Medtronic delivers surgical tools for bariatric procedures. Allurion Technologies offers non-surgical intragastric balloon treatment.
Barriers to entry include the lengthy drug development timeline, clinical trial requirements demonstrating long term safety and efficacy, payer coverage negotiations, and established prescriber relationships. Strategic priorities include expanding GLP-1 agonist access, developing combination therapies, and building patient support programs.
Key Companies in the Obesity Management Market
Key global companies leading the obesity management market include:
- Novo Nordisk A/S, Eli Lilly and Company, Johnson and Johnson (Ethicon) maintain leadership through established market presence and product portfolios.
- Medtronic plc, Allurion Technologies have established positions through specialized capabilities.
- Obalon Therapeutics, ReShape Lifesciences, Apollo Endosurgery, Aspire Bariatrics are among the emerging players gaining traction.
Competitive Benchmarking: Obesity Management Market
| Company | Treatment Portfolio | Clinical Evidence | Prescriber Access | Geographic Coverage |
|---|---|---|---|---|
| Novo Nordisk | High | Strong | Extensive | Global |
| Eli Lilly | High | Strong | Extensive | Global |
| J&J (Ethicon) | Medium | Strong | Strong | Global |
| Medtronic plc | Medium | Moderate | Strong | Global |
| Allurion Technologies | Low | Moderate | Growing | Global |
| Obalon Therapeutics | Low | Moderate | Limited | N. America |
| ReShape Lifesciences | Low | Moderate | Limited | N. America |
Source: Future Market Insights competitive analysis, 2026.
Key Players in the Obesity Management Market
Major Global Players
- Novo Nordisk A/S
- Eli Lilly and Company
- Johnson and Johnson (Ethicon)
- Medtronic plc
- Allurion Technologies
Emerging Players/Startups
- Obalon Therapeutics
- ReShape Lifesciences
- Apollo Endosurgery
- Aspire Bariatrics
- BAROnova, Inc.
Report Scope and Coverage
| Metric | Value |
|---|---|
| Quantitative Units | USD 2.41 billion to USD 3.89 billion, at a CAGR of 4.9% |
| Market Definition | The Obesity Management Market covers pharmaceutical drugs and surgical procedures used for weight management in patients with obesity. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | USA, UK, Germany, South Korea, Japan, China, India, France, 30 plus countries |
| Key Companies Profiled | Novo Nordisk, Eli Lilly, Johnson and Johnson (Ethicon), Medtronic plc, Allurion Technologies, Obalon Therapeutics, ReShape Lifesciences, Apollo Endosurgery, Aspire Bariatrics |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom up and top down methodology starting with verified transaction data, projecting adoption velocity across segments and regions. |
Segmentation
Obesity Management Market Segmented by Drug Type:
- Liraglutide
- Bupropion and Naltrexone
- Orlistat
- Lorcaserin
- Phentermine and Topiramate
Obesity Management Market Segmented by Surgery Type:
- Gastric Bypass Surgery
- Adjustable Gastric Banding Surgery
- Gastric Sleeve Surgery
- Duodenal Switch Surgery
- Others
Obesity Management Market Segmented by Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- E-commerce
Obesity Management Market Segmented by Route of Administration:
- Oral
- Injectable
Obesity Management Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- 1. World Health Organization. (2025). WHO Obesity and Overweight Fact Sheet. WHO.
- 2. USA Food and Drug Administration. (2025). FDA Approved Medications for Obesity Treatment. FDA.
- 3. European Medicines Agency. (2024). EMA Assessment Report: GLP-1 Agonists for Weight Management. EMA.
- 4. National Institutes of Health. (2025). NIH Clinical Guidelines for Obesity Management. NIH.
- 5. International Federation for the Surgery of Obesity and Metabolic Disorders. (2025). IFSO Global Registry Report. IFSO.
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.
This Report Answers
- Estimating market size and revenue projections from 2026 to 2036.
- Segmentation by drug type, surgery type, distribution channel, and route of administration.
- Regional insights covering more than 30 markets.
- Analysis of pharmacological and surgical treatment categories.
- Competitive landscape assessment.
- Growth opportunity identification in GLP-1 agonists and minimally invasive bariatric procedures.
- Supply chain evaluation.
- Data delivery in PDF and Excel formats.
Frequently Asked Questions
What is the global market demand for Obesity Management in 2026?
In 2026, the global market is expected to be worth USD 2.41 billion.
How big will the market be in 2036?
By 2036, the market is expected to be worth USD 3.89 billion.
How much is demand expected to grow?
Between 2026 and 2036, demand is expected to grow at a CAGR of 4.9%.
Which surgery type leads in 2026?
Gastric Bypass Surgery holds 45.0% of the surgery type segment, reflecting established long term outcomes data.
What drives demand in the USA?
The USA at 5.2% reflects high obesity prevalence, GLP-1 adoption, and bariatric surgery infrastructure.
What drives demand in South Korea?
South Korea at 5.1% reflects rising obesity rates and expanding treatment options.
What is the market definition?
The market covers pharmaceutical drugs and surgical procedures for weight management in obesity.
How is the forecast validated?
Hybrid bottom up and top down approach using verified treatment data validated against epidemiology and manufacturer disclosures.
Table of Content
- Executive Summary
- Global Market Outlook
- Demand to side Trends
- Supply to side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- FMI Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y to o to Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Drug Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Drug Type, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Drug Type, 2026 to 2036
- Liraglutide
- Bupropion and Naltrexone
- Orlistat
- Lorcaserin
- Phentermine and Topiramate
- Liraglutide
- Y to o to Y Growth Trend Analysis By Drug Type, 2021 to 2025
- Absolute $ Opportunity Analysis By Drug Type, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Surgery Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Surgery Type, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Surgery Type, 2026 to 2036
- Gastric Bypass Surgery
- Adjustable Gastric Banding Surgery
- Gastric Sleeve Surgery
- Duodenal Switch Surgery
- Others
- Gastric Bypass Surgery
- Y to o to Y Growth Trend Analysis By Surgery Type, 2021 to 2025
- Absolute $ Opportunity Analysis By Surgery Type, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Distribution Channel
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Distribution Channel, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Distribution Channel, 2026 to 2036
- Hospitals Pharmacies
- Retail Pharmacies
- E-commerce
- Hospitals Pharmacies
- Y to o to Y Growth Trend Analysis By Distribution Channel, 2021 to 2025
- Absolute $ Opportunity Analysis By Distribution Channel, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Route of Administration
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Route of Administration, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Route of Administration, 2026 to 2036
- Oral
- Injectable
- Oral
- Y to o to Y Growth Trend Analysis By Route of Administration, 2021 to 2025
- Absolute $ Opportunity Analysis By Route of Administration, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Drug Type
- By Surgery Type
- By Distribution Channel
- By Route of Administration
- Competition Analysis
- Competition Deep Dive
- Novo Nordisk A/S
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Eli Lilly and Company
- Johnson & Johnson (Ethicon & Bariatric Surgery Division)
- Medtronic plc
- Allurion Technologies
- Novo Nordisk A/S
- Competition Deep Dive
- Assumptions & Acronyms Used
List of Tables
- Table 1: Global Market Value (USD Million) Forecast by Region, 2021 to 2036
- Table 2: Global Market Value (USD Million) Forecast by Drug Type, 2021 to 2036
- Table 3: Global Market Value (USD Million) Forecast by Surgery Type, 2021 to 2036
- Table 4: Global Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
- Table 5: Global Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
- Table 6: North America Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 7: North America Market Value (USD Million) Forecast by Drug Type, 2021 to 2036
- Table 8: North America Market Value (USD Million) Forecast by Surgery Type, 2021 to 2036
- Table 9: North America Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
- Table 10: North America Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
- Table 11: Latin America Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 12: Latin America Market Value (USD Million) Forecast by Drug Type, 2021 to 2036
- Table 13: Latin America Market Value (USD Million) Forecast by Surgery Type, 2021 to 2036
- Table 14: Latin America Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
- Table 15: Latin America Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
- Table 16: Western Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 17: Western Europe Market Value (USD Million) Forecast by Drug Type, 2021 to 2036
- Table 18: Western Europe Market Value (USD Million) Forecast by Surgery Type, 2021 to 2036
- Table 19: Western Europe Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
- Table 20: Western Europe Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
- Table 21: Eastern Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 22: Eastern Europe Market Value (USD Million) Forecast by Drug Type, 2021 to 2036
- Table 23: Eastern Europe Market Value (USD Million) Forecast by Surgery Type, 2021 to 2036
- Table 24: Eastern Europe Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
- Table 25: Eastern Europe Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
- Table 26: East Asia Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 27: East Asia Market Value (USD Million) Forecast by Drug Type, 2021 to 2036
- Table 28: East Asia Market Value (USD Million) Forecast by Surgery Type, 2021 to 2036
- Table 29: East Asia Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
- Table 30: East Asia Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
- Table 31: South Asia and Pacific Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 32: South Asia and Pacific Market Value (USD Million) Forecast by Drug Type, 2021 to 2036
- Table 33: South Asia and Pacific Market Value (USD Million) Forecast by Surgery Type, 2021 to 2036
- Table 34: South Asia and Pacific Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
- Table 35: South Asia and Pacific Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
- Table 36: Middle East & Africa Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 37: Middle East & Africa Market Value (USD Million) Forecast by Drug Type, 2021 to 2036
- Table 38: Middle East & Africa Market Value (USD Million) Forecast by Surgery Type, 2021 to 2036
- Table 39: Middle East & Africa Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
- Table 40: Middle East & Africa Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
List of Figures
- Figure 1: Global Market Pricing Analysis
- Figure 2: Global Market Value (USD Million) Forecast 2021-2036
- Figure 3: Global Market Value Share and BPS Analysis by Drug Type, 2026 and 2036
- Figure 4: Global Market Y-o-Y Growth Comparison by Drug Type, 2026-2036
- Figure 5: Global Market Attractiveness Analysis by Drug Type
- Figure 6: Global Market Value Share and BPS Analysis by Surgery Type, 2026 and 2036
- Figure 7: Global Market Y-o-Y Growth Comparison by Surgery Type, 2026-2036
- Figure 8: Global Market Attractiveness Analysis by Surgery Type
- Figure 9: Global Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
- Figure 10: Global Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
- Figure 11: Global Market Attractiveness Analysis by Distribution Channel
- Figure 12: Global Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
- Figure 13: Global Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
- Figure 14: Global Market Attractiveness Analysis by Route of Administration
- Figure 15: Global Market Value (USD Million) Share and BPS Analysis by Region, 2026 and 2036
- Figure 16: Global Market Y-o-Y Growth Comparison by Region, 2026-2036
- Figure 17: Global Market Attractiveness Analysis by Region
- Figure 18: North America Market Incremental Dollar Opportunity, 2026-2036
- Figure 19: Latin America Market Incremental Dollar Opportunity, 2026-2036
- Figure 20: Western Europe Market Incremental Dollar Opportunity, 2026-2036
- Figure 21: Eastern Europe Market Incremental Dollar Opportunity, 2026-2036
- Figure 22: East Asia Market Incremental Dollar Opportunity, 2026-2036
- Figure 23: South Asia and Pacific Market Incremental Dollar Opportunity, 2026-2036
- Figure 24: Middle East & Africa Market Incremental Dollar Opportunity, 2026-2036
- Figure 25: North America Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 26: North America Market Value Share and BPS Analysis by Drug Type, 2026 and 2036
- Figure 27: North America Market Y-o-Y Growth Comparison by Drug Type, 2026-2036
- Figure 28: North America Market Attractiveness Analysis by Drug Type
- Figure 29: North America Market Value Share and BPS Analysis by Surgery Type, 2026 and 2036
- Figure 30: North America Market Y-o-Y Growth Comparison by Surgery Type, 2026-2036
- Figure 31: North America Market Attractiveness Analysis by Surgery Type
- Figure 32: North America Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
- Figure 33: North America Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
- Figure 34: North America Market Attractiveness Analysis by Distribution Channel
- Figure 35: North America Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
- Figure 36: North America Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
- Figure 37: North America Market Attractiveness Analysis by Route of Administration
- Figure 38: Latin America Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 39: Latin America Market Value Share and BPS Analysis by Drug Type, 2026 and 2036
- Figure 40: Latin America Market Y-o-Y Growth Comparison by Drug Type, 2026-2036
- Figure 41: Latin America Market Attractiveness Analysis by Drug Type
- Figure 42: Latin America Market Value Share and BPS Analysis by Surgery Type, 2026 and 2036
- Figure 43: Latin America Market Y-o-Y Growth Comparison by Surgery Type, 2026-2036
- Figure 44: Latin America Market Attractiveness Analysis by Surgery Type
- Figure 45: Latin America Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
- Figure 46: Latin America Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
- Figure 47: Latin America Market Attractiveness Analysis by Distribution Channel
- Figure 48: Latin America Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
- Figure 49: Latin America Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
- Figure 50: Latin America Market Attractiveness Analysis by Route of Administration
- Figure 51: Western Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 52: Western Europe Market Value Share and BPS Analysis by Drug Type, 2026 and 2036
- Figure 53: Western Europe Market Y-o-Y Growth Comparison by Drug Type, 2026-2036
- Figure 54: Western Europe Market Attractiveness Analysis by Drug Type
- Figure 55: Western Europe Market Value Share and BPS Analysis by Surgery Type, 2026 and 2036
- Figure 56: Western Europe Market Y-o-Y Growth Comparison by Surgery Type, 2026-2036
- Figure 57: Western Europe Market Attractiveness Analysis by Surgery Type
- Figure 58: Western Europe Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
- Figure 59: Western Europe Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
- Figure 60: Western Europe Market Attractiveness Analysis by Distribution Channel
- Figure 61: Western Europe Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
- Figure 62: Western Europe Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
- Figure 63: Western Europe Market Attractiveness Analysis by Route of Administration
- Figure 64: Eastern Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 65: Eastern Europe Market Value Share and BPS Analysis by Drug Type, 2026 and 2036
- Figure 66: Eastern Europe Market Y-o-Y Growth Comparison by Drug Type, 2026-2036
- Figure 67: Eastern Europe Market Attractiveness Analysis by Drug Type
- Figure 68: Eastern Europe Market Value Share and BPS Analysis by Surgery Type, 2026 and 2036
- Figure 69: Eastern Europe Market Y-o-Y Growth Comparison by Surgery Type, 2026-2036
- Figure 70: Eastern Europe Market Attractiveness Analysis by Surgery Type
- Figure 71: Eastern Europe Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
- Figure 72: Eastern Europe Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
- Figure 73: Eastern Europe Market Attractiveness Analysis by Distribution Channel
- Figure 74: Eastern Europe Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
- Figure 75: Eastern Europe Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
- Figure 76: Eastern Europe Market Attractiveness Analysis by Route of Administration
- Figure 77: East Asia Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 78: East Asia Market Value Share and BPS Analysis by Drug Type, 2026 and 2036
- Figure 79: East Asia Market Y-o-Y Growth Comparison by Drug Type, 2026-2036
- Figure 80: East Asia Market Attractiveness Analysis by Drug Type
- Figure 81: East Asia Market Value Share and BPS Analysis by Surgery Type, 2026 and 2036
- Figure 82: East Asia Market Y-o-Y Growth Comparison by Surgery Type, 2026-2036
- Figure 83: East Asia Market Attractiveness Analysis by Surgery Type
- Figure 84: East Asia Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
- Figure 85: East Asia Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
- Figure 86: East Asia Market Attractiveness Analysis by Distribution Channel
- Figure 87: East Asia Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
- Figure 88: East Asia Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
- Figure 89: East Asia Market Attractiveness Analysis by Route of Administration
- Figure 90: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 91: South Asia and Pacific Market Value Share and BPS Analysis by Drug Type, 2026 and 2036
- Figure 92: South Asia and Pacific Market Y-o-Y Growth Comparison by Drug Type, 2026-2036
- Figure 93: South Asia and Pacific Market Attractiveness Analysis by Drug Type
- Figure 94: South Asia and Pacific Market Value Share and BPS Analysis by Surgery Type, 2026 and 2036
- Figure 95: South Asia and Pacific Market Y-o-Y Growth Comparison by Surgery Type, 2026-2036
- Figure 96: South Asia and Pacific Market Attractiveness Analysis by Surgery Type
- Figure 97: South Asia and Pacific Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
- Figure 98: South Asia and Pacific Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
- Figure 99: South Asia and Pacific Market Attractiveness Analysis by Distribution Channel
- Figure 100: South Asia and Pacific Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
- Figure 101: South Asia and Pacific Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
- Figure 102: South Asia and Pacific Market Attractiveness Analysis by Route of Administration
- Figure 103: Middle East & Africa Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 104: Middle East & Africa Market Value Share and BPS Analysis by Drug Type, 2026 and 2036
- Figure 105: Middle East & Africa Market Y-o-Y Growth Comparison by Drug Type, 2026-2036
- Figure 106: Middle East & Africa Market Attractiveness Analysis by Drug Type
- Figure 107: Middle East & Africa Market Value Share and BPS Analysis by Surgery Type, 2026 and 2036
- Figure 108: Middle East & Africa Market Y-o-Y Growth Comparison by Surgery Type, 2026-2036
- Figure 109: Middle East & Africa Market Attractiveness Analysis by Surgery Type
- Figure 110: Middle East & Africa Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
- Figure 111: Middle East & Africa Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
- Figure 112: Middle East & Africa Market Attractiveness Analysis by Distribution Channel
- Figure 113: Middle East & Africa Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
- Figure 114: Middle East & Africa Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
- Figure 115: Middle East & Africa Market Attractiveness Analysis by Route of Administration
- Figure 116: Global Market - Tier Structure Analysis
- Figure 117: Global Market - Company Share Analysis
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
